Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy - Takeaways - MDSpire

Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy

  • By

  • Aluminé Lezcano

  • Emanuel Miculan

  • Geronimo Ducca

  • Carolina Ruera

  • María Luz Iribarren

  • Philippe Tixador

  • Xavier Roux

  • Fernando Gabriel Chirdo

  • July 6, 2026

  • 0 min

Share

  • 1

    Saccharomyces boulardii CNCM I-745 significantly improved histological parameters in a mouse model of gliadin-peptide-induced small intestinal inflammation.

  • 2

    Concomitant treatment with Sb restored the villus-height-to-crypt-depth ratio and reduced intraepithelial lymphocyte infiltration.

  • 3

    Sb treatment prevented the upregulation of Cxcl10 expression and attenuated caspase-1 activation in the context of inflammation.

  • 4

    The probiotic yeast Sb also reduced cell death associated with gliadin peptide treatment in the small intestine.

  • 5

    These findings suggest that Sb may play a role in mitigating inflammation-induced damage in the small intestine.

Original Source(s)

Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy

  • by Aluminé Lezcano, Emanuel Miculan, Geronimo Ducca, Carolina Ruera, María Luz Iribarren, Philippe Tixador, Xavier Roux, Fernando Gabriel Chirdo

  • July 6, 2026

Related Content

Proton Pump Inhibitors and Cancer Risk

Investigators evaluate cancer risk tied to extended acid suppression therapy.

Immunogenetic HLA-DQ and IgG serological profiles in individuals with self-reported wheat/gluten sensitivity: a retrospective real-world evidence study

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.